Peripheral nervous system cells (PNS cells)

The peripheral nervous system (PNS) encompasses the vast network of nerves and ganglia located outside the brain and spinal cord, serving as the primary communication relay between the central nervous system and the body's limbs and organs [1]. It is composed of diverse cell populations, including sensory and motor neurons, as well as specialized glial cells like Schwann cells, which provide myelination and trophic support [1, 2]. While the PNS as a whole is a physiological system rather than a single molecular target, it contains numerous specific therapeutic targets such as voltage-gated sodium channels (e.g., Nav1.7) and transient receptor potential (TRP) channels involved in pain signaling [3]. Pharmacological intervention typically involves modulating these specific receptors or channels to treat conditions such as chronic pain, peripheral neuropathy, and inflammatory demyelinating disorders [2, 3]. Therapeutic challenges include achieving high specificity for peripheral isoforms to avoid central nervous system side effects and addressing the complex regenerative environment of peripheral nerves [4]. Sources: [1] StatPearls, Physiology, Peripheral Nervous System; [2] NIH/NINDS, Peripheral Neuropathy Fact Sheet; [3] Nature Reviews Drug Discovery, Ion channels as drug targets in pain; [4] Journal of the Peripheral Nervous System, Biomarkers for peripheral neuropathy.

Other names

Peripheral neuronsPeripheral gliaPeripheral nerve fibersGanglion cellsSchwann cells

Drugs typically act by modulating specific molecular components within these cells, such as blocking voltage-gated sodium channels (e.g., Nav1.7, Nav1.8) to inhibit pain signaling, binding to the alpha-2-delta subunit of voltage-gated calcium channels to reduce excitatory neurotransmitter release, or inhibiting the reuptake of serotonin and norepinephrine to enhance descending inhibitory pain pathways.